Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The pathogenesis of Burkitt's lymphoma.

× No keyword cloud information.

85 in total

1. Tissue inhibitor of metalloproteinase-1 alters the tumorigenicity of Burkitt's lymphoma via divergent effects on tumor growth and angiogenesis.

Authors: L Guedez; A J McMarlin; D W Kingma; T A Bennett; M Stetler-Stevenson; W G Stetler-Stevenson
Journal: Am J Pathol Date: 2001-04 Impact factor: 4.307

2. c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells.

Authors: M A Gregory; S R Hann
Journal: Mol Cell Biol Date: 2000-04 Impact factor: 4.272

Review 3. Burkitt's lymphoma: new insights into molecular pathogenesis.

Authors: C Bellan; S Lazzi; G De Falco; A Nyongo; A Giordano; L Leoncini
Journal: J Clin Pathol Date: 2003-03 Impact factor: 3.411

4. Epstein-Barr virus small RNAs potentiate tumorigenicity of Burkitt lymphoma cells independently of an effect on apoptosis.

Authors: I K Ruf; P W Rhyne; C Yang; J L Cleveland; J T Sample
Journal: J Virol Date: 2000-11 Impact factor: 5.103

Review 5. The involvement of oncogenes and tumor suppressor genes in the control of apoptosis.

Authors: M Oren
Journal: Cancer Metastasis Rev Date: 1992-09 Impact factor: 9.264

6. Improved long-distance polymerase chain reaction for the detection of t(8;14)(q24;q32) in Burkitt's lymphomas.

Authors: K Basso; E Frascella; L Zanesco; A Rosolen
Journal: Am J Pathol Date: 1999-11 Impact factor: 4.307

7. Activation of c-myc promoter P1 by immunoglobulin kappa gene enhancers in Burkitt lymphoma: functional characterization of the intron enhancer motifs kappaB, E box 1 and E box 2, and of the 3' enhancer motif PU.

Authors: N E Wittekindt; K Hörtnagel; C Geltinger; A Polack
Journal: Nucleic Acids Res Date: 2000-02-01 Impact factor: 16.971

Review 8. Control of viral disease: the development of Epstein-Barr virus vaccines.

Authors: A J Morgan
Journal: Springer Semin Immunopathol Date: 1991

9. Rapamycin reverses splenomegaly and inhibits tumor development in a transgenic model of Epstein-Barr virus-related Burkitt's lymphoma.

Authors: Osman Cen; Richard Longnecker
Journal: Mol Cancer Ther Date: 2011-01-31 Impact factor: 6.261

10. Two acquired immunodeficiency syndrome-associated Burkitt's lymphomas produce specific anti-i IgM cold agglutinins using somatically mutated VH4-21 segments.

Authors: P Riboldi; G Gaidano; E W Schettino; T G Steger; D M Knowles; R Dalla-Favera; P Casali
Journal: Blood Date: 1994-05-15 Impact factor: 22.113